Interestingly, a recent case report showed that rebastinib, a TIE2 inhibitor (Fig. 1), reduced lesion size and improve quality of life in a patient with a severe cervicofacial venous malformation (Triana and Lopez-Gutierrez, 2023). The gene discussed is TEK; the disease is Venous malformation.